Last reviewed · How we verify
NCT06052319: IPACE-CVD
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
trial testing Care4Today® Connect CAD-PAD Mobile Application in Coronary Artery Disease (CAD) in 277 participants. Completed in 13 August 2024.
13 August 2024
Quick facts
| Lead sponsor | Janssen Scientific Affairs, LLC |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 277 |
| Start date | 29 November 2023 |
| Primary completion | 13 August 2024 |
| Estimated completion | 13 August 2024 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- Care4Today® Connect CAD-PAD Mobile Application
Conditions studied
- Coronary Artery Disease (CAD) — all drugs for Coronary Artery Disease (CAD) →
- Peripheral Artery Disease (PAD) — all drugs for Peripheral Artery Disease (PAD) →
Sponsor
Janssen Scientific Affairs, LLC — full company profile →
Who can join
Adults 40 to 90, any sex, with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the engagement and usefulness of Care4Today® Connect CAD-PAD digital platform in participants with coronary artery disease or peripheral artery disease (CAD or PAD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rationale and Design of a Study to Assess the Engagement and Usefulness of the Care4Today Connect Digital Health Application for Disease Management in Coronary Artery Disease and Peripheral Artery Disease (iPACE-CVD Study).
Lakkireddy D, Angiolillo DJ, Charlton-Ouw K, Jefferson B, et al · · 2024 · PMID 39663755 · DOI 10.1002/clc.70039
Verify or expand the search:
- PubMed search for NCT06052319
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease (CAD)
Currently open trials in the same condition.
- NCT07479433 — The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI · recruiting
- NCT07349875 — Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial · Phase 4 · recruiting
- NCT07277686 — AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population · recruiting
- NCT07148518 — Comparison of Upper and Lower Limb Maximal Exercise Capacities and Arterial Stiffness in Patients With CAD · recruiting
- NCT07392021 — Effects of a Recovery-Promoting Program in Patients Undergoing CABG Surgery · NA · active not recruiting
Other Janssen Scientific Affairs, LLC trials
Trials by the same sponsor.
- NCT05347485 — A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma · Phase 2 · completed
- NCT04372108 — A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcera · recruiting
- NCT04442737 — A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Re · Phase 4 · completed
- NCT04276441 — A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World · completed
- NCT03464136 — Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06052319 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Scientific Affairs, LLC
- Last refreshed: 27 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06052319.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing